Abstract
Background:
Metastatic castration-resistant prostate cancer (mCRPC) is an arduous treatment despite improved systemic treatment. New androgen receptor inhibitors (ARIs) are extremely effective in their efficacy, yet their efficacy and safety profiles in the clinic need to be compared.
Aim:
This randomized controlled trial sought to determine if the efficacy and safety of new ARIs is comparable to best available therapy in patients with mCRPC.
Methods:
Confirmed mCRPC patients were randomized to new ARIs or conventional androgen-deprivation therapy. Progression-free survival (PFS), overall survival (OS), prostate-specific antigen (PSA) response, and adverse events related to treatment were the endpoints.
Results:
Patients treated with ARIs had much better PFS and OS than with standard treatment. PSA response rates were better in the patient group receiving ARIs, and the concerns regarding safety were manageable and occurred in the form of fatigue and hypertension only.
Conclusion:
New generation ARIs significantly enhance survival outcome and disease control in men with mCRPC with an acceptable safety profile to include them as a component of standard treatment protocols.
Keywords: